Esperion Therapeutics Inc (ESPR) Receives $87.36 Consensus Price Target from Brokerages

Esperion Therapeutics Inc (NASDAQ:ESPR) has been given an average rating of “Buy” by the sixteen ratings firms that are presently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $90.62.

A number of research analysts have recently issued reports on the company. BidaskClub downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $65.00 price target (up from $55.00) on shares of Esperion Therapeutics in a report on Wednesday, February 21st. UBS set a $90.00 price target on Esperion Therapeutics and gave the company a “neutral” rating in a report on Wednesday, February 21st. Needham & Company LLC raised Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and upped their price target for the company from $72.00 to $81.00 in a report on Thursday, December 14th. Finally, Chardan Capital upped their price target on Esperion Therapeutics from $20.00 to $75.00 and gave the company a “neutral” rating in a report on Wednesday, December 6th.

How to Become a New Pot Stock Millionaire

Shares of ESPR stock traded down $0.20 during trading hours on Friday, hitting $70.17. The stock had a trading volume of 557,153 shares, compared to its average volume of 709,905. The company has a market capitalization of $1,859.43, a P/E ratio of -10.00 and a beta of 2.45. Esperion Therapeutics has a 1 year low of $30.95 and a 1 year high of $82.68.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.80) by $0.36. During the same period in the prior year, the company earned ($1.29) EPS. equities analysts expect that Esperion Therapeutics will post -5.66 earnings per share for the current fiscal year.

In other Esperion Therapeutics news, Director Nicole Vitullo sold 11,674 shares of the stock in a transaction dated Thursday, January 25th. The stock was sold at an average price of $71.79, for a total value of $838,076.46. Following the transaction, the director now owns 3,177 shares of the company’s stock, valued at $228,076.83. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 32.50% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the business. Meditor Group Ltd lifted its holdings in Esperion Therapeutics by 1.2% in the fourth quarter. Meditor Group Ltd now owns 2,322,835 shares of the biopharmaceutical company’s stock valued at $152,935,000 after acquiring an additional 27,900 shares during the period. Millennium Management LLC increased its position in Esperion Therapeutics by 1,062.7% in the fourth quarter. Millennium Management LLC now owns 387,947 shares of the biopharmaceutical company’s stock worth $25,542,000 after buying an additional 354,580 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec purchased a new stake in Esperion Therapeutics in the third quarter worth about $12,583,000. Amundi Pioneer Asset Management Inc. increased its position in Esperion Therapeutics by 25.5% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 238,384 shares of the biopharmaceutical company’s stock worth $15,695,000 after buying an additional 48,485 shares in the last quarter. Finally, MUFG Securities EMEA plc purchased a new stake in Esperion Therapeutics in the third quarter worth about $9,022,000. 91.66% of the stock is currently owned by institutional investors.

WARNING: “Esperion Therapeutics Inc (ESPR) Receives $87.36 Consensus Price Target from Brokerages” was published by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3300589/esperion-therapeutics-inc-espr-receives-87-36-consensus-price-target-from-brokerages.html.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

MKS Instruments  Releases Q2 Earnings Guidance
MKS Instruments Releases Q2 Earnings Guidance
Vipshop  versus Qurate Retail Group  Critical Contrast
Vipshop versus Qurate Retail Group Critical Contrast
Reviewing Chunghwa Telecom  and Cellcom
Reviewing Chunghwa Telecom and Cellcom
Gnosis  Market Capitalization Hits $123.05 Million
Gnosis Market Capitalization Hits $123.05 Million
VoteCoin Price Up 215% This Week
VoteCoin Price Up 215% This Week
Dashcoin  Tops One Day Volume of $1,507.00
Dashcoin Tops One Day Volume of $1,507.00


© 2006-2018 Ticker Report. Google+.